Zentalis Pharmaceuticals, Inc. Stock Analysis & AI Score
Zentalis Pharmaceuticals, Inc. (ZNTL) has an ST Score of 34.2 (C-), driven by its Forecast (A) and held back by its Profitability (D-). Analysts rate it Buy with a $8.33 price target (+202.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Zentalis Pharmaceuticals, Inc. (ZNTL) has an ST Score of 34.2 (C-), driven by its Forecast (A) and held back by its Profitability (D-). Analysts rate it Buy with a $8.33 price target (+202.9% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityD-
All factor grades
- ForecastA
- ValuationC
- MomentumC
- Financial StrengthD+
- GrowthD+
- ProfitabilityD-
- Piotroski2/9
Contact
ZNTL stock: frequently asked questions
What is ZNTL's ST Score?
Zentalis Pharmaceuticals, Inc. (ZNTL) has an ST Score of 34.2 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ZNTL a buy, hold, or sell?
Analysts rate ZNTL a Buy, with a price target of $8.33 (+202.9% vs the current price). Our ST Score grades it C- (34.2/100). The ST Score is a data-driven signal, not a recommendation.
What are ZNTL's factor grades?
Valuation C, Profitability D-, Financial Strength D+, Momentum C, Growth D+, Forecast A.
What is ZNTL's valuation grade?
Zentalis Pharmaceuticals, Inc. (ZNTL) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ZNTL's growth grade?
Zentalis Pharmaceuticals, Inc. (ZNTL) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ZNTL's profitability grade?
Zentalis Pharmaceuticals, Inc. (ZNTL) earns a profitability grade of D-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ZNTL's financial strength grade?
Zentalis Pharmaceuticals, Inc. (ZNTL) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ZNTL?
The average analyst price target for Zentalis Pharmaceuticals, Inc. (ZNTL) is $8.33 from 12 analysts, which is +202.9% versus the recent price of $2.75.
What is ZNTL's Piotroski score?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.